Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for fenebrutinib under priority review for relapsing and primary progressive multiple sclerosis.
In the Phase III FENhance 1 and 2 trials, fenebrutinib reduced annualised relapse rates by 51.1% and 58.5%, respectively, versus teriflunomide over 96 weeks, while disability progression measures showed consistent positive trends favouring fenebrutinib.
In the Phase III FENtrepid study, fenebrutinib met its primary endpoint of non-inferiority to Ocrevus in reducing disability progression and numerically reduced the risk of progression by 12%.
Genentech said fenebrutinib is designed to target acute inflammation associated with relapses and chronic inflammation thought to drive disability progression by crossing the blood-brain barrier into the central nervous system.
Serious adverse event rates were 9% for both fenebrutinib and teriflunomide in FENhance 1, 11% versus 6% in FENhance 2, and 19% for both fenebrutinib and Ocrevus in FENtrepid.
The company said fenebrutinib has demonstrated a manageable safety profile across Phase III and earlier studies, with a safety database comprising more than 2,700 participants.
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
SciBase technology selected as primary endpoint in NIH-led skin exposure study
argenx reports positive Phase 2 results for FB102 in coeliac disease
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
AFYREN ingredient enables global launch of natural propionic acid skincare product